Our findings are in line with previous studies associating high CD8 + with low CD163 + count with favorable DFS in breast cancer patients [5, 42]; (ii) we demonstrated the differential impact of proliferating CD8 + /TCF1 + T cells as well as CD163 + infiltrating cells and PD-L1 status on DFS between luminal A and TNBC tumors. The gene discussed is CD8A; the disease is breast cancer.